Rocket Pharmaceuticals voluntarily withdrew its FDA submission for its Fanconi anemia gene therapy. The move follows a corporate restructuring over the summer that refocused the company on its cardiovascular programs.
The post Rocket Pharmaceuticals Pulls FDA Filing for Rare Blood Disorder Gene Therapy appeared first on MedCity News.
